What is OS Therapies's proceeds from royalties received?

OS Therapies (OSTX) reported proceeds from royalties received of $150K in Q1 2024.

What does proceeds from royalties received mean?

The total cash inflows generated from licensing intellectual property or technology to third parties. This represents a recurring revenue stream derived from the commercialization of the company's proprietary assets.

OS Therapies OSTX Proceeds From Royalties Received

Proceeds From Royalties Received at other companies

Perrigo CompanyPRGO

$1.4M-17.6%

Lightwave Logic, Inc.LWLG

$50K—

Lexicon PharmaceuticalsLXRX

$12K—

Elanco Animal Health Inc.ELAN

$9M—

10x Genomics, Inc.TXG

$947K-94.4%

Aclaris TherapeuticsACRS

$854K+2.5%

Other financials

Income statement

See full

Operating income-$10.2M-103%

Net income-$10.4M-168%

EPS (diluted)-$0.27-50.0%

Balance sheet

See full

Cash & equivalents$917.6K-69.1%

Total debt$20.0M—

Total equity-$10.8M-159%

Total assets$7.3M+71.7%

Cash flow

See full

Operating cash flow-$4.6M-32.6%

CapEx$316.4K—

Free cash flow-$3.7M—

Valuation

See full

Market cap$84.62M+65.5%

Enterprise value$103.7M—

Returns & leverage

See full

Return on equity470%—

Debt / equity-1.8×—

Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromRoyaltiesReceived.

The official record: OS Therapies’s 10-Q, filed May 20, 2024, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's proceeds from royalties received.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OS Therapies's proceeds from royalties received?: OS Therapies (OSTX) reported proceeds from royalties received of $150K in Q1 2024.
What does proceeds from royalties received mean?: The total cash inflows generated from licensing intellectual property or technology to third parties. This represents a recurring revenue stream derived from the commercialization of the company's proprietary assets.